Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 128Lung Neoplasms 49Breast Neoplasms 24Head and Neck Neoplasms 21Adenocarcinoma of Lung 18Brain Neoplasms 15Neoplasms 14Adenocarcinoma, Bronchiolo-Alveolar 11Squamous Cell Carcinoma of Head and Neck 10Glioblastoma 9Esophageal Neoplasms 9Colorectal Neoplasms 9Rectal Neoplasms 7Prostatic Neoplasms 7Neoplasm Metastasis 7NSCLC 7Gliosarcoma 7Colonic Neoplasms 7Adenocarcinoma Of Esophagus 7Ovarian Neoplasms 5Esophageal Squamous Cell Carcinoma 5Adenocarcinoma 5Urinary Bladder Neoplasms 4Central Nervous System Neoplasms 4Carcinoma, Renal Cell 4Carcinoma 4Unspecified Adult Solid Tumor, Protocol Specific 3Skin Neoplasms 3Respiratory Tract Diseases 3Kidney Neoplasms 3

Interventions

cediranib 1Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Tumor × Gefitinib × Clear all
NCT00502060 2009-05-14

Phase I Study of AZD2171 co-Administered With Fixed Multiple Oral Doses of ZD1839 in Patients With Advanced Cancer

AstraZeneca

Phase 1 Completed
65 enrolled

Advanced Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡